Heterozygous mice for TGF-βIIR gene are resistant to the progression of streptozotocin-induced diabetic nephropathy

Kidney International

Volumn 66, Issue 5, 2004, Pages 1859-1865

  Hwal, Woong Kim ^a   Bong, Cho Kim ^a   Chi, Young Song ^a   Ji, Hoon Kim ^a   Hye, Kyoung Hong ^a   Hyun, Soon Lee ^a  

^a Seoul National University   (South Korea)

Author keywords

CAGA sequence; Extracellular matrix; Smad signaling

Indexed keywords

SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; DNA BINDING PROTEIN; SMAD2 PROTEIN, MOUSE; SMAD3 PROTEIN, MOUSE; TRANSACTIVATOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LABELING; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DOWNSTREAM PROCESSING; GENE EXPRESSION; GLOMERULOSCLEROSIS; HETEROZYGOSITY; HISTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; C57BL MOUSE; CYTOCHEMISTRY; EXPERIMENTAL DIABETES MELLITUS; GENETICS; GLOMERULUS; HETEROZYGOTE; MESANGIUM; METABOLISM; NORTHERN BLOTTING; PATHOLOGY;

ANIMALS; BLOTTING, NORTHERN; DIABETES MELLITUS, EXPERIMENTAL; DISEASE PROGRESSION; DNA-BINDING PROTEINS; GLOMERULAR MESANGIUM; HETEROZYGOTE; HISTOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; KIDNEY GLOMERULUS; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANS-ACTIVATORS;

EID: 21644463253     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00959.x     Document Type: Article

References (41)

1. COHEN MP, SHARMA K, JIN Y, et al: Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists: A novel treatment strategy. J Clin Invest 95:2338-2345, 1995
2. KOYA D, HANEDA M, NAKAGAWA H, et al: Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14:439-447, 2000
3. PARK IS, KIYOMOTO H, ABBOUD SL, ABBOUD HE: Expression of transforming growth factor-β and type IV collagen in early streptozotocin-induced diabetes. Diabetes 46:473-480, 1997
4. PAUEKSAKON P, REVELO MP, MA L-J, et al: Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy. Kidney Int 61:2142-2148, 2003
5. FRANZEN P, TEN DIJKE P, ICHIJO H, et al: Cloning of a TGF-β type I receptor that forms a heteromeric complex with TGF-β type II receptor. Cell 75:681-692, 1994
6. BLOBE GC, SCHIEMANN WP, LODISH HF: Role of transforming growth factor β in human disease. N Engl J Med 342:1350-1358, 2000
7. NAKAO A, IMAMURA T, SOUCHELNYTSKYI S, et al: TGF-β receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J 16:5353-5362, 1997
8. MIYAZONO K, TEN DIJKE P, HELDIN C-H: TGF-β signaling by Smad proteins. Adv Immunol 75:115-157, 2000
9. ZAWEL L, DAI JL, BUCKHAULTS P, et al: Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1:611-617, 1998
10. DENNLER S, ITOH S, VIVIEN D, et al: Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promotor of human plasminogen activator inhibitor-type I gene. EMBO J 17:3091-3100, 1998
11. HUA X, MILLER ZA, WU G, et al: Specificity in transforming growth factor β-induced transcription of the plasminogen activator inhibitor-1 gene: Interactions of promoter DNA, transcription factor μE3, and Smad proteins. Proc Natl Acad Sci USA 96:13130-13135, 1999
12. STROSCHEIN SL, WANG W, LUO K: Cooperative binding of Smad proteins to two adjacent DNA elements in the plasminogen activator inhibitor-1 promoter mediates transforming growth factor β-induced Smad-dependent transcriptional activation. J Biol Chem 274:9431-9441, 1999
13. PONCELET AC, SCHNAPER HW: Sp1 and Smad proteins cooperate to mediate transforming growth factor-β1-induced α2(I) collagen expression in human glomerular mesangial cells. J Biol Chem 276:6983-6992, 2001
14. RISER BL, LADSON-WOFFORD S, SHARBA A, et al: TGF-β receptor expression and binding in rat mesangial cells: Modulation by glucose and cyclic mechanical strain. Kidney Int 56:428-439, 1999
15. ISONO M, MOGYOROSI A, HAN DC, et al: Stimulation of TGF-β type II receptor by high glucose in mouse mesangial cells and in diabetic kidney. Am J Phyisol Renal Physiol 278:F830-F838, 2000
16. HILL C, FLYVBJERG A, GRONBAEK H, et al: The renal expression of transforming growth factor-β isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology 141:1196-1208, 2000
17. KANG MJ, INGRAM A, LY H, et al: Effects of diabetes and hypertension on glomerular transforming growth factor-β receptor expression. Kidney Int 58:1677-1685, 2000
18. IGLESIAS-DE LA CRUZ MC, ZIYADEH FN, ISONO M, et al: Effects of high glucose and TGF-β1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int 62:901-913, 2002
19. HONG SW, ISONO M, CHEN S, et al: Increased glomerular and tubular expression of transforming growth factor-β1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 158:1653-1663, 2001
20. OSHIMA M, OSHIMA H, TAKETO MM: TGF-β receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol 179:297-302, 1996
21. IM Y-H, KIM HT, KIM IY, et al: Heterozygous mice for the transforming growth factor-β type II receptor gene have increased susceptibility to hepatocellular carcinogenesis. Cancer Res 61:6665-6668, 2001
22. WEIBEL ER, GOMEZ DM: A principle for counting tissue structures on random sections. J Appl Physiol 17:343-348, 1962
23. LEE HS, KOH HI: Nature of progressive glomerulosclerosis in human membranous nephropathy. Clin Nephrol 39:7-16, 1993
24. HERNANDEZ-PRESA MA, GOMEZ-GUERRERO C, EGIDO J: In situ non-radioactive detection of nuclear factors in paraffin sections by Southwestern histochemistry. Technical note. Kidney Int 55:209-214, 1999
25. LEE HS, KIM BC, KIM YS, et al: Involvement of oxidation in LDL-induced collagen gene regulation in mesangial cells. Kidney Int 50:1582-1590, 1996
26. KIM JH, KIM BK, MOON KC, et al: Activation of the TGF-β/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int 64:1715-1721, 2003
27. YAGI K, GOTO D, HAMAMOTO T, et al: Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3. J Biol Chem 274:703-709, 1999
28. MOUSTAKAS A, SOUCHELNYTSKYI S, HELDIN C-H: Smad regulation in TGF-β signal transduction. J Cell Sci 114:4359-4369, 2001
29. ZHAO J, SHI W, WANG YL, et al: Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 282:L585-L593, 2002
30. ISONO M, CHEN S, HONG SW, et al: Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-β-induced fibronectin in mesangial cells. Biochem Biophy Res Comm 296:1356-1365, 2002
31. DATTA PK, BLAKE MC, MOSES HL: Regulation of plasminogen activator inhibitor-1 expression by transforming growth factor-β-induced physical and functional interactions between Smads and Sp1. J Biol Chem 275:40014-40019, 2000
32. MASSAGUE J, CHEN YG: Controlling TGF-β signaling. Genes Dev 14:627-644, 2000
33. VERRECCHIA F, MAUVIEL A: Transforming growth factor-β signaling through the Smad pathway: Role in extracellular matrix gene expression and regulation. J Invest Dermatol 118:211-215, 2002
34. TSUCHIDA K-I, ZHU Y, SIVA S, et al: Role of Smad4 on TGF-β-induced extracellular matrix stimulation in mesangial cells. Kidney Int 63:2000-2009, 2003
35. MASSAGUE J, WOTTON D: Transcriptional control by TGF-β/Smad signaling. EMBO J 19:1745-1754, 2000
36. HIROSE K, OSTERBY R, NOZAWA M, GUNDERSEN HJG: Development of glomerular lesions in experimental long-term diabetes in the rat. Kidney Int 21:689-695, 1982
37. BORDER WA, OKUDA S, LANGUINO LR, et al: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 346:371-374, 1990
38. SHARMA K, JIN Y, Guo J, ZIYADEH FN: Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45:522-530, 1996
39. ZIYADEH FN, HOFFMAN BB, HAN DC, et al: Long-term prevention of renal insufficiency, excess matrix gene expression and glomerular mesangial matrix expansion by treatment with monoclonal anti-TGF-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015-8020, 2000
40. CALLAHAN JF, BURGESS JL, FORNWALD JA, et al: Identification of novel inhibitors of the transforming growth factor β1 (TGF-β1) type I receptor (ALK5). J Med Chem 45:999-1001, 2002
41. LAPING NJ, GRYGIELKO E, MATHUR A, et al: Inhibition of transforming growth factor (TGF)-β1-induced extracellular matrix with a novel inhibitor of the TGF-β type I receptor kinase activity: SB-431542. Mol Pharmacol 62:58-64, 2002